Company Overview of AlphaVax, Inc.
AlphaVax, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of vaccine candidates for infectious disease prevention and cancer immunotherapy. The company’s alphavccine candidates targeting human cytomegalovirus, influenza A virus, or HIV-1 are in clinical trials. Its alphavaccine technology is based on its replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis virus. The company’s products are used in various cancer treatments, such as colon cancer, breast cancer, and melanoma. AlphaVax, Inc. was founded in 1997 and is based in Research Triangle Park, North Carolina.
2 Triangle Drive
P.O. Box 110307
Research Triangle Park, NC 27709-0307
Founded in 1997
Key Executives for AlphaVax, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact AlphaVax, Inc., please visit www.alphavax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.